Stents having biodegradable layers
A method for preparing a laminate coronary stent comprising: providing a stent framework; and depositing a plurality of layers on said stent framework to form said laminate coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer.
1. A laminate stent comprising:
a. a stent framework;
b. a plurality of layers on said stent framework to form said laminate stent, where at least one of said layers comprises a bioabsorbable polymer; and
c. a layer of macrolide immunosuppressive (limus) drug in crystalline form and an extracellular matrix comprising an interlocking mesh of fibrous proteins and glycosaminoglycans (GAGs).
2. The laminate coronary stent of claim 1 , wherein the stent framework includes a plurality of struts, each strut having a luminal, abluminal and soluble surfaces, and wherein said at least one layer comprising the bioabsorbable polymer includes a plurality of bioabsorbable polymer layers deposited on the luminal, abluminal, and soluble surfaces.
3. The laminate coronary stent of claim 2 , wherein each of said plurality of bioabsorbable polymer layers is sintered.
4. The laminate coronary stent of claim 2 , wherein said plurality of bioabsorbable polymer layers and said layer of at least one active agent in crystalline form, form a coating on said stent framework, said coating consisting essentially of said plurality of bioabsorbable polymer layers and said layer of at least one active agent in crystalline form.
5. The laminate coronary stent of claim 2 , including 4, 10, 20, 50, and 100 or more of said plurality of bioabsorbable polymer layers.
6. The laminate coronary stent of claim 1 , wherein said stent framework is composed of a bioabsorbable polymer or a conductive polymer.
7. The laminate coronary stent of claim 1 , wherein said stent framework is composed of biocompatible-non-bioabsorbable material.
8. The laminate coronary stent of claim 1 , wherein said stent framework is composed of stainless steel.
9. The laminate coronary stent of claim 1 , wherein said bioabsorbable polymer is selected from PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e caprolactone), PDQ poly(dioxlane), PGA-TMC, 85115 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPLG, 65/35 DLPLG, 50/50 DLPLG, TMC polytrimethylcarbonate), p(CPP:SA) ply(1,3-bis-p (carboxyphenoxy)propane-co-sebacic acid).
10. The laminate coronary stent of claim 1 , wherein said macrolide immunosuppressive drug comprises one or more of rapamycin, 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′: E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin, 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin, 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3 S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N Methyl-N′-piperazinyl) acetoxy]ethyl-rapamycin, 39-0-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin, 40-O-(2-Nicotinamidoethyl) rapamycin, 40-O-(2-(N-Methyl-imidazo-T-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′ Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-tetrazolyl)rapamycin (tacrolimus), and 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus).